Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2019-01 Issue:1 Volume:20 Page:88-99
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Mamounas Eleftherios P,Bandos Hanna,Lembersky Barry C,Jeong Jong-Hyeon,Geyer Charles E,Rastogi Priya,Fehrenbacher Louis,Graham Mark L,Chia Stephen K,Brufsky Adam M,Walshe Janice M,Soori Gamini S,Dakhil Shaker R,Seay Thomas E,Wade James L,McCarron Edward C,Paik Soonmyung,Swain Sandra M,Wickerham D Lawrence,Wolmark Norman

Funder

US Department of Health and Human Services, Public Health Service

Ministry of Health and Welfare, Republic of Korea

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Tamoxifen for early breast cancer: an overview of the randomised trials;Lancet,1998

2. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;N Engl J Med,2017

3. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer;Goss;N Engl J Med,2003

4. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial;Mamounas;J Clin Oncol,2008

5. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial;Davies;Lancet,2013

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL;Journal of Bone and Mineral Metabolism;2024-08-13

2. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial;Journal of Clinical Oncology;2024-07-24

3. Drug-induced osteoporosis and mechanisms of bone tissue regeneration through trace elements;Journal of Trace Elements in Medicine and Biology;2024-07

4. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS);Clinical Breast Cancer;2024-06

5. Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials;eClinicalMedicine;2024-04